Research / PRHI / Fundamental state Inspectable configuration
State dimensions Filing 0000950170-25-046719 Insurance
Cash 75th Own-history percentile · N=12
Evidence method Level · gp.fundamentals.cash
$27.7M · CORE · VALID
Debt 0th Own-history percentile · N=12
Evidence method Level · gp.fundamentals.gross_debt
$11.9M · OPTIONAL · VALID
Premium growth 25th Own-history percentile · N=8
Evidence method Yoy · gp.insurance.premiums
-27.49% · CORE · VALID
Revenue growth 13th Own-history percentile · N=8
Evidence method Yoy · gp.fundamentals.revenue
-31.88% · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 15 states Self-history eligible
Dec 31, 2022 0/4 normalized Level 3 Mar 31, 2023 0/4 normalized Level 3 Jun 30, 2023 0/4 normalized Level 3 Sep 30, 2023 0/4 normalized Level 3 Dec 31, 2023 2/4 normalized Level 3 Mar 31, 2024 2/5 normalized Level 3 Jun 30, 2024 2/4 normalized Level 3 Sep 30, 2024 2/4 normalized Level 3 Dec 31, 2024 4/4 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 4/4 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 4/5 normalized Level 3 Mar 31, 2026 4/5 normalized Level 3 Jun 30, 2026 4/5 normalized Level 4 Period transition
What moved in the state? Cash Decreased
Previous $32.4M
Current $27.7M
Delta -$4.7M Debt Decreased
Previous $16.5M
Current $11.9M
Delta -$4.5M Premium Growth Increased
Previous -39.11%
Current -27.49%
Delta 11.62% Revenue Growth Increased
Previous -43.03%
Current -31.88%
Delta 11.15% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.